Promoter hypermethylation of SFRP1 as a prognostic and potentially predictive blood-based biomarker in patients with localized pancreatic ductal adenocarcinoma

INTRODUCTION: Current prognostic blood-based biomarkers for pancreatic adenocarcinoma (PDAC) are limited. Recently, promoter hypermethylation of SFRP1 (phSFRP1) has been linked to poor prognosis in patients with gemcitabine-treated stage IV PDAC. This study explores the effects of phSFRP1 in patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Stubbe, Benjamin Emil, Larsen, Anders Christian, Madsen, Poul Henning, Krarup, Henrik Bygum, Pedersen, Inge Søkilde, Lundbye-Christensen, Søren, Hansen, Carsten Palnæs, Hasselby, Jane Preuss, Johansen, Astrid Zedlitz, Thorlacius-Ussing, Ole, Johansen, Julia Sidenius, Henriksen, Stine Dam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272559/
https://www.ncbi.nlm.nih.gov/pubmed/37333823
http://dx.doi.org/10.3389/fonc.2023.1211292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272559/
https://www.ncbi.nlm.nih.gov/pubmed/37333823
http://dx.doi.org/10.3389/fonc.2023.1211292

Ejemplares similares